Indraprastha Medical Corporation profit and loss

Latest FY26

Revenue: ₹1,483cr+9.3% on FY25
EBITDA: ₹267cr+9.3% on FY25
Net profit: ₹184cr+14.1% on FY25
EPS: ₹20.03+14.1% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	1,555	1,483	1,356	1,245	1,099	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	31.5	28.8	22.7	16.9	10.0
	1,587	1,511	1,379	1,262	1,109
	266	256	230	217	194
	301	288	277	262	247
	6.3	6.0	6.3	4.1	4.3
	46.6	43.6	44.3	40.1	39.3
	710	672	605	573	508
	1,329	1,265	1,163	1,095	992
	280	267	244	193	151
	233	223	200	153	111
Profit
	258	246	216	166	117
	258	246	216	166	117
	60.6	57.9	59.4	43.0	31.1
	5.6	4.5	−4.1	−0.9	−0.1
	66.2	62.4	55.3	42.2	31.0
	192	184	161	124	86.2
	192	184	161	124	86.2
	0.6	1.3	−0.8	1.9	−9.2
	193	185	160	126	76.9
Per share
	₹20.95	₹20.03	₹17.56	₹13.52	₹9.40
	₹14.86	₹20.03	₹17.56	₹13.52	₹9.40
Other comprehensive income — detail
	0.6	1.3	−0.8	—	—
	0.8	1.8	−1.1	2.5	−12.3
	0.2	0.4	−0.3	—	—
	—	—	—	0.6	−3.1
Per share — as-filed variants
	₹20.95	₹20.03	₹17.56	₹13.52	₹9.40
	₹14.86	₹20.03	₹17.56	₹13.52	₹9.40
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,290	1,226	1,126	1,028	905
	82.9%	82.7%	83.0%	82.6%	82.4%
Adjusted (ex-exceptional items) — derived
	258	246	216	166	117
	192	184	161	124	86.2
	₹20.95	₹20.03	₹17.56	₹13.52	₹9.40

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

INDRAMEDCO₹300.00

Indraprastha Medical Corporation Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersARTEMISMED SHALBY GKSL GPTHEALTH LOTUSEYE DRAGARWQ KMCSHIL KOVAIMcap ₹2,750 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,098.7	1,244.7	1,356.4	1,482.5	1,555.4
Other Income	10.0	16.9	22.7	28.8	31.5
Total Income	1,108.7	1,261.6	1,379.0	1,511.3	1,586.9
Expenses
+ Cost of Materials Consumed	193.6	217.2	230.5	256.3	265.6
+ Employee Benefit Expense	246.7	261.6	277.1	287.6	300.6
+ Finance Costs	4.3	4.1	6.3	6.0	6.3
+ Depreciation & Amortisation	39.3	40.1	44.3	43.6	46.6
+ Other Expenses	507.7	572.5	604.5	671.7	709.6
Total Expenses	991.5	1,095.5	1,162.7	1,265.2	1,328.6
EBITDA	150.7	193.4	244.3	266.9	279.7
EBIT	111.4	153.3	199.9	223.3	233.1
Profit
PBT before Exceptional Items	117.2	166.1	216.3	246.0	258.3
Pretax Income	117.2	166.1	216.3	246.0	258.3
+ Current Tax	31.1	43.0	59.4	57.9	60.6
+ Deferred Tax	-0.1	-0.9	-4.1	4.5	5.6
Tax Expense	31.0	42.2	55.3	62.4	66.2
Net Income	86.2	124.0	161.0	183.6	192.1
+ Net Income — Continuing Ops	86.2	124.0	161.0	183.6	192.1
+ Other Comprehensive Income	-9.2	1.9	-0.8	1.3	0.6
Total Comprehensive Income	76.9	125.8	160.2	184.9	192.7
Per Share
Basic EPS	9.40	13.52	17.56	20.03	20.95
Diluted EPS	9.40	13.52	17.56	20.03	14.86
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.8	1.3	0.6
+ Items NOT to be Reclassified to P&L	-12.3	2.5	-1.1	1.8	0.8
+ Tax on Items NOT to be Reclassified	—	—	-0.3	0.4	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-3.1	0.6	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	9.40	13.52	17.56	20.03	20.95
Diluted EPS — Continuing Operations	9.40	13.52	17.56	20.03	14.86
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	905.1	1,027.5	1,125.9	1,226.2	1,289.8
Gross Margin %	82.38	82.55	83.01	82.71	82.92
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	117.2	166.1	216.3	246.0	258.3
Net Income Adj (tax-effected)	86.2	124.0	161.0	183.6	192.1
EPS Adj	9.40	13.52	17.56	20.03	20.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	91.7	91.7	91.7	91.7	91.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.